Ipamorelin FAQ: Research, Safety, and CJC-1295 Questions Answered
Does ipamorelin reduce belly fat?
No human trial shows ipamorelin reduces belly fat. The most relevant recent data is a 2024 ferret study where intraperitoneal ipamorelin (1 to 3 mg/kg) inhibited chemotherapy-induced body-weight loss by about 24% in the delayed phase, which is weight defense, not fat reduction [5]. Community reports of a gradually leaner look are anecdotal and confounded by diet and training, not clinical evidence [16].
Is there new research on ipamorelin in 2024?
Yes. The most recent in-vivo study is a 2024 ferret experiment in which intraperitoneal ipamorelin (1 to 3 mg/kg) cut cisplatin-induced body-weight loss by roughly 24% on the last day of the delayed phase, though it had no anti-emetic effect [5]. Several 2026 reviews then synthesized ipamorelin as an investigational growth-hormone-axis peptide still lacking rigorous human trials [16][18].
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and the first highly selective growth-hormone secretagogue [1]. It releases growth hormone potently (swine ED50 2.3 nmol/kg) by activating the ghrelin receptor (GHS-R1a), yet does not meaningfully raise cortisol or prolactin even at doses 200-fold above its growth-hormone ED50 [1]. It is a research peptide, not an approved drug [3].
What does ipamorelin do for you?
In the research, ipamorelin triggers a clean pulse of growth hormone by acting on the ghrelin receptor, without the cortisol and prolactin rise seen with older peptides [1]. Animal studies show bone growth [4] and body-weight protection [5]. It has no proven human health benefit: its only Phase 2 efficacy trial missed its endpoint [3], so claims of personal benefit are not clinically established.
What is ipamorelin peptide?
The ipamorelin peptide is a wholly synthetic five-amino-acid chain (Aib-His-D-2-Nal-D-Phe-Lys-NH2, about 712 Da) designed to mimic ghrelin at the GHS-R1a receptor [1]. Its non-natural building blocks make it resistant to enzymatic breakdown, and its defining feature is selective growth-hormone release without cortisol or prolactin elevation [1]. Its development code was NNC 26-0161 [1].
What are the risks of ipamorelin?
The clearest documented limitation is failed efficacy: the only Phase 2 RCT (NCT00672074, n=114, 0.03 mg/kg IV twice daily) missed its primary endpoint, 25.3 h vs 32.6 h placebo (p=0.15) [3]. Class-level concerns include a cardiotoxicity signal in a 28-day rat study of a related ghrelin-receptor agonist [6] and a theoretical IGF-1-driven proliferation risk [4]. Long-term human safety is uncharacterized [3].
What are the downsides of ipamorelin?
The main downside in the evidence is that it has never been shown to work in a human efficacy trial: its Phase 2 ileus study missed its primary endpoint (p=0.15) [3]. Add no approved indication, no long-term human safety data, a class-level rat cardiotoxicity signal [6], and unverified research-grade purity [3]. Reported side effects like flushing and water retention are anecdotal.
Why is ipamorelin being discontinued?
Ipamorelin was never an approved product, so it cannot be "discontinued" as a drug. Its clinical development stopped because its only Phase 2 trial, for postoperative ileus, missed its primary endpoint (25.3 h vs 32.6 h placebo, p=0.15) and no Phase 3 followed [3]. Separately, in 2024 the FDA removed ipamorelin acetate from the interim 503A Category 2 list, restricting compounding access.
What does CJC-1295 and ipamorelin do?
Together they stimulate the growth-hormone axis through two complementary pathways: CJC-1295 (a GHRH analog) drives sustained output and durable IGF-1 elevation [10], and ipamorelin adds a pulsatile ghrelin-receptor release [1]. A 2026 USC review found the combination improved peak muscle force in a steroid-induced muscle-loss mouse model, but stressed the evidence is animal-only [15]. No controlled human combination trial exists [3].
Does ipamorelin increase IGF-1?
Indirectly and inconsistently. Growth hormone can prompt the liver to produce IGF-1, but in a 15-day rat bone-growth study ipamorelin raised bone growth with no measurable change in total IGF-1, suggesting partly local, pulse-driven effects [4]. In sustained off-label GHS combinations, an observational report in men did find raised serum IGF-1 [11]. So IGF-1 elevation is context-dependent, not guaranteed.
How does CJC-1295 ipamorelin work?
They hit two different receptors. CJC-1295 acts on the GHRH receptor (cAMP pathway) for sustained growth-hormone output [10]; ipamorelin acts on the ghrelin receptor GHS-R1a (calcium pathway) for a pulsatile release [1]. Because pulsatile secretion persists even under continuous GHRH stimulation [9], combining a steady and a pulsatile signal is additive, the mechanistic basis for the pairing. No combination trial has tested it in humans [3].
How much CJC-1295 ipamorelin should I take?
There is no evidence-based dose, because no controlled human trial has tested the combination at any dose for any outcome [3]. Community subcutaneous "stack" protocols have no peer-reviewed human pharmacokinetic or efficacy basis and are anecdotal, not recommended [3]. The literature establishes only single-agent pharmacology, such as ipamorelin's ~2-hour human half-life [2]. This site does not provide a personal dose.
Does CJC-1295 ipamorelin work?
Biologically each peptide raises growth-hormone output through complementary pathways [1][10], and an observational report found combined GHS therapy raised IGF-1 in men [11]. For a specific human health outcome the combination is unproven, no controlled trial exists [3]. The strongest combination evidence is a 2026 mouse study showing improved muscle force, explicitly limited to animals [15].
How to reconstitute CJC-1295 ipamorelin 5mg?
The literature gives only general peptide-handling notes, not a clinical procedure. Ipamorelin is supplied as a lyophilized (freeze-dried) powder and reconstituted with bacteriostatic water for research handling [2]. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is kept refrigerated. These are research-supply observations, not preparation or dosing instructions, and no approved formulation exists [3].
How long does ipamorelin stay in your system?
Not long. In healthy human volunteers ipamorelin had a terminal half-life of approximately 2 hours after IV dosing, with clearance of 0.078 L/h/kg [2]. The growth-hormone pulse it triggers peaks at about 40 minutes (0.67 h) after dosing as a single discrete spike [2]. Because growth-hormone secretagogues are detectable in urine, anti-doping labs can still identify use after the parent peptide has cleared [7].
Does ipamorelin make you hungry?
It can, by mechanism. Ipamorelin acts on the ghrelin (hunger-hormone) receptor, and ghrelin-receptor agonists activate brain appetite centers and induce feeding as a class [14]. In community reports, increased hunger after injection is occasionally noted, generally described as milder than with GHRP-6, anecdotal, not clinical evidence. Animal data also show GH-independent appetite and adiposity effects [13].
Will I gain weight on ipamorelin?
The evidence is mixed and indirect. In a 2024 ferret study ipamorelin protected against chemotherapy-driven weight loss [5], and mouse studies show GH-independent increases in adiposity and leptin [13]. But there is no human weight-change trial, and the one human efficacy trial measured bowel recovery, not body weight [3]. Reported "leaner look" effects are anecdotal and confounded by diet and training.
Does ipamorelin increase appetite?
By mechanism it can. As a ghrelin-receptor agonist, it engages the same receptor as the natural hunger hormone, and central administration of ghrelin and GH secretagogues activates appetite centers and induces feeding in animals [14]. Mouse data also show GH-independent stimulation of adiposity and food intake [13]. In community reports, increased appetite after injection is occasionally mentioned but is anecdotal.
What does ipamorelin peptide do?
The ipamorelin peptide selectively activates the ghrelin receptor (GHS-R1a) on the pituitary to release a clean pulse of growth hormone, without meaningfully raising cortisol or prolactin even far above its growth-hormone ED50 [1]. In animals this drives bone growth [4] and body-weight defense [5]. It has no proven human therapeutic effect; its sole Phase 2 trial missed its endpoint [3].
How long does it take for ipamorelin to work?
On the molecular level it works within the hour: the growth-hormone pulse it triggers peaks around 40 minutes after dosing in humans [2]. Any subjective effects people report, like sleep changes, are anecdotal and described as appearing over one to two weeks, not clinical findings. There is no validated human onset timeline for any health outcome, since no efficacy trial succeeded [3].
Does ipamorelin cause water retention?
Mild water retention is occasionally reported in research-use communities, typically transient puffiness in the first few weeks, anecdotal, not clinical evidence. Mechanistically it is plausible: growth-hormone excess (as in acromegaly) is associated with sodium and water retention [6]. No ipamorelin trial has measured fluid balance as an endpoint, so there is no clinical confirmation either way [3].
Where to inject CJC-1295 ipamorelin?
This site does not give injection instructions. For context only: in research, the subcutaneous (under-the-skin) route is the dominant one in community use, while human trials used the intravenous route [2]. Because no controlled human protocol for the combination exists [3], there is no validated administration guidance to report, and nothing here should be read as a how-to.